Cyclosporine A impairs the macrophage reverse cholesterol transport in mice by reducing sterol fecal excretion.

Despite the efficacy in reducing acute rejection events in organ transplanted subjects, long term therapy with cyclosporine A is associated with increased atherosclerotic cardiovascular morbidity. We studied whether this drug affects the antiatherogenic process of the reverse cholesterol transport f...

Full description

Bibliographic Details
Main Authors: Ilaria Zanotti, Daniela Greco, Giulia Lusardi, Francesca Zimetti, Francesco Potì, Lorenzo Arnaboldi, Alberto Corsini, Franco Bernini
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3739729?pdf=render
_version_ 1828200614016843776
author Ilaria Zanotti
Daniela Greco
Giulia Lusardi
Francesca Zimetti
Francesco Potì
Lorenzo Arnaboldi
Alberto Corsini
Franco Bernini
author_facet Ilaria Zanotti
Daniela Greco
Giulia Lusardi
Francesca Zimetti
Francesco Potì
Lorenzo Arnaboldi
Alberto Corsini
Franco Bernini
author_sort Ilaria Zanotti
collection DOAJ
description Despite the efficacy in reducing acute rejection events in organ transplanted subjects, long term therapy with cyclosporine A is associated with increased atherosclerotic cardiovascular morbidity. We studied whether this drug affects the antiatherogenic process of the reverse cholesterol transport from macrophages in vivo. Cyclosporine A 50 mg/kg/d was administered to C57BL/6 mice by subcutaneous injection for 14 days. Macrophage reverse cholesterol transport was assessed by following [(3)H]-cholesterol mobilization from pre-labeled intraperitoneally injected macrophages, expressing or not apolipoprotein E, to plasma, liver and feces. The pharmacological treatment significantly reduced the amount of radioactive sterols in the feces, independently on the expression of apolipoprotein E in the macrophages injected into recipient mice and in absence of changes of plasma levels of high density lipoprotein-cholesterol. Gene expression analysis revealed that cyclosporine A inhibited the hepatic levels of cholesterol 7-alpha-hydroxylase, concomitantly with the increase in hepatic and intestinal expression of ATP Binding Cassette G5. However, the in vivo relevance of the last observation was challenged by the demonstration that mice treated or not with cyclosporine A showed the same levels of circulating beta-sitosterol. These results indicate that treatment of mice with cyclosporine A impaired the macrophage reverse cholesterol transport by reducing fecal sterol excretion, possibly through the inhibition of cholesterol 7-alpha-hydroxylase expression. The current observation may provide a potential mechanism for the high incidence of atherosclerotic coronary artery disease following the immunosuppressant therapy in organ transplanted recipients.
first_indexed 2024-04-12T11:17:11Z
format Article
id doaj.art-bb534d5349364b48be4a39e857b063e4
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-12T11:17:11Z
publishDate 2013-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-bb534d5349364b48be4a39e857b063e42022-12-22T03:35:28ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0188e7157210.1371/journal.pone.0071572Cyclosporine A impairs the macrophage reverse cholesterol transport in mice by reducing sterol fecal excretion.Ilaria ZanottiDaniela GrecoGiulia LusardiFrancesca ZimettiFrancesco PotìLorenzo ArnaboldiAlberto CorsiniFranco BerniniDespite the efficacy in reducing acute rejection events in organ transplanted subjects, long term therapy with cyclosporine A is associated with increased atherosclerotic cardiovascular morbidity. We studied whether this drug affects the antiatherogenic process of the reverse cholesterol transport from macrophages in vivo. Cyclosporine A 50 mg/kg/d was administered to C57BL/6 mice by subcutaneous injection for 14 days. Macrophage reverse cholesterol transport was assessed by following [(3)H]-cholesterol mobilization from pre-labeled intraperitoneally injected macrophages, expressing or not apolipoprotein E, to plasma, liver and feces. The pharmacological treatment significantly reduced the amount of radioactive sterols in the feces, independently on the expression of apolipoprotein E in the macrophages injected into recipient mice and in absence of changes of plasma levels of high density lipoprotein-cholesterol. Gene expression analysis revealed that cyclosporine A inhibited the hepatic levels of cholesterol 7-alpha-hydroxylase, concomitantly with the increase in hepatic and intestinal expression of ATP Binding Cassette G5. However, the in vivo relevance of the last observation was challenged by the demonstration that mice treated or not with cyclosporine A showed the same levels of circulating beta-sitosterol. These results indicate that treatment of mice with cyclosporine A impaired the macrophage reverse cholesterol transport by reducing fecal sterol excretion, possibly through the inhibition of cholesterol 7-alpha-hydroxylase expression. The current observation may provide a potential mechanism for the high incidence of atherosclerotic coronary artery disease following the immunosuppressant therapy in organ transplanted recipients.http://europepmc.org/articles/PMC3739729?pdf=render
spellingShingle Ilaria Zanotti
Daniela Greco
Giulia Lusardi
Francesca Zimetti
Francesco Potì
Lorenzo Arnaboldi
Alberto Corsini
Franco Bernini
Cyclosporine A impairs the macrophage reverse cholesterol transport in mice by reducing sterol fecal excretion.
PLoS ONE
title Cyclosporine A impairs the macrophage reverse cholesterol transport in mice by reducing sterol fecal excretion.
title_full Cyclosporine A impairs the macrophage reverse cholesterol transport in mice by reducing sterol fecal excretion.
title_fullStr Cyclosporine A impairs the macrophage reverse cholesterol transport in mice by reducing sterol fecal excretion.
title_full_unstemmed Cyclosporine A impairs the macrophage reverse cholesterol transport in mice by reducing sterol fecal excretion.
title_short Cyclosporine A impairs the macrophage reverse cholesterol transport in mice by reducing sterol fecal excretion.
title_sort cyclosporine a impairs the macrophage reverse cholesterol transport in mice by reducing sterol fecal excretion
url http://europepmc.org/articles/PMC3739729?pdf=render
work_keys_str_mv AT ilariazanotti cyclosporineaimpairsthemacrophagereversecholesteroltransportinmicebyreducingsterolfecalexcretion
AT danielagreco cyclosporineaimpairsthemacrophagereversecholesteroltransportinmicebyreducingsterolfecalexcretion
AT giulialusardi cyclosporineaimpairsthemacrophagereversecholesteroltransportinmicebyreducingsterolfecalexcretion
AT francescazimetti cyclosporineaimpairsthemacrophagereversecholesteroltransportinmicebyreducingsterolfecalexcretion
AT francescopoti cyclosporineaimpairsthemacrophagereversecholesteroltransportinmicebyreducingsterolfecalexcretion
AT lorenzoarnaboldi cyclosporineaimpairsthemacrophagereversecholesteroltransportinmicebyreducingsterolfecalexcretion
AT albertocorsini cyclosporineaimpairsthemacrophagereversecholesteroltransportinmicebyreducingsterolfecalexcretion
AT francobernini cyclosporineaimpairsthemacrophagereversecholesteroltransportinmicebyreducingsterolfecalexcretion